An­dreessen Horowitz-backed start­up lands $200M for AI-based drug dis­cov­ery

Gen­e­sis Ther­a­peu­tics, a start­up us­ing ar­ti­fi­cial in­tel­li­gence to de­sign small mol­e­cule drugs, has raised $200 mil­lion in Se­ries B fi­nanc­ing — one of the largest rounds for an AI-fo­cused biotech this year.

The round is be­ing co-led by An­dreessen Horowitz (a16z) Bio + Health and an anony­mous life sci­ence in­vestor. The Burlingame, CA-based com­pa­ny, which pre­vi­ous­ly struck part­ner­ships with Eli Lil­ly and Genen­tech, will use the mon­ey to fur­ther de­vel­op its gen­er­a­tive and pre­dic­tive AI tech­nolo­gies, ex­pand its pipeline, and move its first com­put­er-gen­er­at­ed drugs in­to clin­i­cal stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER